Emily Wenande1, Uffe H Olesen1, Mette M B Nielsen2, Christian Janfelt3, Steen Honoré Hansen3, R Rox Anderson4, Merete Haedersdal1,4. 1. a Department of Dermatology , Copenhagen University Hospital Bispebjerg , Copenhagen , Denmark. 2. b Department of Drug Design and Pharmacology , University of Copenhagen , Copenhagen , Denmark. 3. c Department of Pharmacy , University of Copenhagen , Copenhagen , Denmark. 4. d Wellman Center for Photomedicine , Massachusetts General Hospital, Harvard Medical School , Boston , MA , USA.
Abstract
BACKGROUND: Topical 5-Fluorouracil (5-FU) exhibits suboptimal efficacy for non-melanoma skin cancer, attributed to insufficient intracutaneous penetration. This study investigates the impact of ablative fractional laser (AFXL) at different laser-channel depths on cutaneous 5-FU pharmacokinetics and biodistribution. METHODS: In vitro porcine skin underwent AFXL-exposure using a fractional 10,600 nm CO2-laser, generating microscopic ablation zones (MAZ) reaching the dermoepidermal junction (MAZ-ED), superficial-(MAZ-DS), or mid-dermis(MAZ-DM). 5-FU in AFXL-exposed and control skin was measured in Franz diffusion cells at 4 and 24 hours (n = 55). HPLC quantified 5-FU in full-thickness skin, specific skin depths of 100μm-1500μm, and transcutaneous receiver-compartments. Qualitative matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) visualized 5-FU in selected samples. RESULTS: Overall, AFXL enhanced and accelerated 5-FU uptake versus unexposed controls, with increased accumulation in deep skin layers (p < 0.01). While total, 24-hour 5-FU uptake in control skin was 0.096 mg/cm3 (0.19% of applied concentration), AFXL delivered up to 4.707 mg/cm3 (MAZ-DM; 9.41% uptake, 49-fold enhancement) (p = 0.002; 24 hours). Indicating accelerated delivery, 5-FU in laser-exposed samples at 4 hours was at least 10-fold that of 24-hour controls (p = 0.002). Deeper laser-channels increased delivery throughout the skin (MAZ-ED vs. MAZ-DM; p<0.01). MALDI-MSI confirmed enhanced, accelerated, deeper and more uniform 5-FU distribution after AFXL versus controls. CONCLUSIONS: AFXL offers laser-channel depth-dependent, enhanced and accelerated 5-FU uptake, with increased deposition in deep skin layers.
BACKGROUND: Topical 5-Fluorouracil (5-FU) exhibits suboptimal efficacy for non-melanoma skin cancer, attributed to insufficient intracutaneous penetration. This study investigates the impact of ablative fractional laser (AFXL) at different laser-channel depths on cutaneous 5-FU pharmacokinetics and biodistribution. METHODS: In vitro porcine skin underwent AFXL-exposure using a fractional 10,600 nm CO2-laser, generating microscopic ablation zones (MAZ) reaching the dermoepidermal junction (MAZ-ED), superficial-(MAZ-DS), or mid-dermis(MAZ-DM). 5-FU in AFXL-exposed and control skin was measured in Franz diffusion cells at 4 and 24 hours (n = 55). HPLC quantified 5-FU in full-thickness skin, specific skin depths of 100μm-1500μm, and transcutaneous receiver-compartments. Qualitative matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) visualized 5-FU in selected samples. RESULTS: Overall, AFXL enhanced and accelerated 5-FU uptake versus unexposed controls, with increased accumulation in deep skin layers (p < 0.01). While total, 24-hour 5-FU uptake in control skin was 0.096 mg/cm3 (0.19% of applied concentration), AFXL delivered up to 4.707 mg/cm3 (MAZ-DM; 9.41% uptake, 49-fold enhancement) (p = 0.002; 24 hours). Indicating accelerated delivery, 5-FU in laser-exposed samples at 4 hours was at least 10-fold that of 24-hour controls (p = 0.002). Deeper laser-channels increased delivery throughout the skin (MAZ-ED vs. MAZ-DM; p<0.01). MALDI-MSI confirmed enhanced, accelerated, deeper and more uniform 5-FU distribution after AFXL versus controls. CONCLUSIONS:AFXL offers laser-channel depth-dependent, enhanced and accelerated 5-FU uptake, with increased deposition in deep skin layers.
Entities:
Keywords:
5-Fluorouracil; Franz skin permeability diffusion cells; fractional ablative CO2 laser; high performance liquid chromatography; laser-assisted drug delivery; matrix-assisted laser desorption/ionization mass spectrometry imaging; non-melanoma skin cancer
Authors: Lázaro de Sousa Fideles; João Antônio Leal de Miranda; Conceição da Silva Martins; Maria Lucianny Lima Barbosa; Helder Bindá Pimenta; Paulo Vitor de Souza Pimentel; Claudio Silva Teixeira; Marina Alves Sampaio Scafuri; Samuel de Osterno Façanha; João Erivan Façanha Barreto; Poliana Moreira de Medeiros Carvalho; Ariel Gustavo Scafuri; Joabe Lima Araújo; Jefferson Almeida Rocha; Icaro Gusmão Pinto Vieira; Nágila Maria Pontes Silva Ricardo; Matheus da Silva Campelo; Maria Elenir Nobre Pinho Ribeiro; Gerly Anne de Castro Brito; Gilberto Santos Cerqueira Journal: Molecules Date: 2020-06-17 Impact factor: 4.411
Authors: Emily Wenande; Uffe H Olesen; Malene R Boesen; Daniel P Persson; Catharina M Lerche; Stefan Stürup; Bente Gammelgaard; Søren Husted; R Rox Anderson; Merete Haedersdal Journal: Drug Deliv Date: 2018-11 Impact factor: 6.419
Authors: Kristoffer K Hendel; Charlotte Bagger; Uffe H Olesen; Christian Janfelt; Steen H Hansen; Merete Haedersdal; Catharina M Lerche Journal: Drug Deliv Date: 2019-12 Impact factor: 6.419